Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
30
04
2022
accepted:
10
01
2023
revised:
28
12
2022
medline:
6
4
2023
pubmed:
19
1
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
We aimed to describe the current status of infection prevention practices among EBMT centers. Questionnaires were distributed to all 553 EBMT transplant centers to capture clinical practices regarding antimicrobial prophylaxis, protective measures, isolation procedures and growth-factor support of patients undergoing hematopoietic cell transplantation. Responses from 127 centers in 32 countries were obtained. Most centers housed patients in single rooms (autologous-82%; allogeneic-98%), with high-efficiency particulate air (HEPA)-filters (autologous-73%; allogeneic-100%) and positive pressure (autologous-61%; allogeneic-88%). Pre-engraftment G-CSF was utilized by 77 and 31% of centers after autologous and allogeneic transplantation, respectively (P < 0.00001). Antibacterial prophylaxis was provided by 57 and 69% (P = 0.086) of centers and antifungal prophylaxis by 65 and 84% (P = 0.0008) of centers, to patients undergoing autologous and allogeneic transplantation, respectively. Yet, 16 and 3% of centers provided neither antibacterial nor antifungal prophylaxis to patients undergoing autologous and allogeneic transplantation, respectively. Considerable variation existed between centers and across countries in antimicrobial prophylaxis practices, medications employed and duration of preventive therapy. There were considerable discordances between guidelines and daily practices. JACIE accredited and non-accredited centers did not differ significantly in their antimicrobial prophylaxis practices. Whether these differences between transplant centers translated into differences in infectious morbidity, mortality and financial costs, warrants further research.
Identifiants
pubmed: 36653669
doi: 10.1038/s41409-023-01916-6
pii: 10.1038/s41409-023-01916-6
doi:
Substances chimiques
Antifungal Agents
0
Anti-Infective Agents
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414-423Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bow E, Wingard JR. Overview of neutropenic fever syndromes. https://www.uptodate.com/contents/overview-of-neutropenic-fever-syndromes .
Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016;22:505–14.
doi: 10.1016/j.jiac.2016.05.006
pubmed: 27344206
Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25:101–16.
doi: 10.1016/j.hoc.2010.11.008
pubmed: 21236393
Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.
doi: 10.1086/322604
pubmed: 11528564
Kontoyiannis DP, Marr KA, Park BJ, Barbara DA, Elias JA, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–100.
doi: 10.1086/651263
pubmed: 20218877
Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:94–101.
doi: 10.1016/j.bbmt.2012.08.012
Auletta JJ, Kou J, Chen M, Shaw BE. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2021.
Krüger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German society of haematology and oncology. Ann Oncol. 2005;16:1381–90.
doi: 10.1093/annonc/mdi238
pubmed: 15905309
Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A. et al. Antibiotic prophylaxis in neutropenic patients. New evidence, practical decisions. Cancer. 2006;107:1743–51.
doi: 10.1002/cncr.22205
pubmed: 16977651
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15:1143–238.
doi: 10.1016/j.bbmt.2009.06.019
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–e93.
doi: 10.1093/cid/cir073
pubmed: 21258094
National Comprehensive Cancer Network (NCCN). Prevention and Treatment of Cancer-Related Infections. NCCN Guidelines Version 2.2022. Retrieved September 2022 from ( http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive ).
Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, et al. European Conference on Infections in Leukemia (ECIL). Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76:20–37.
doi: 10.1016/j.jinf.2017.10.009
pubmed: 29079323
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221–30.
pubmed: 30085172
Egan G, Robinson PD, Martinez JPD, Alexander S, Ammann RA, Dupuis LL, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. Cancer Med. 2019;8:4536–46.
doi: 10.1002/cam4.2395
pubmed: 31274245
pmcid: 6712447
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043–54.
doi: 10.1200/JCO.18.00374
pubmed: 30179565
Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, et al. Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95:1435–55.
doi: 10.1007/s00277-016-2711-1
pubmed: 27339055
pmcid: 4972852
Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–e272.
doi: 10.1016/S1473-3099(19)30107-0
pubmed: 31153807
Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2021;100:321–36.
doi: 10.1007/s00277-020-04297-8
pubmed: 33079221
Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020;71:226–36.
doi: 10.1093/cid/ciz1082
pubmed: 31676904
Krüger WH, Hornung RJ, Hertenstein B, Kern WV, Kröger N, Ljungman P, et al. Practices of infection disease prevention and management during hematopoietic cell transplantation: a survey from the European Group for Blood and Marrow Transplantation. J Hematother Stem Cell Res. 2001;10:895–903.
doi: 10.1089/152581601317210999
pubmed: 11798516
Trifilio S, Verma A, Mehta J. Antibacterial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transpl. 2004;33:735–9.
doi: 10.1038/sj.bmt.1704423
Hicheri Y, Einsele H, Martino R, Cesaro S, Ljungman P, Cordonnier C. Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Transpl Infect Dis. 2013;15:251–8.
doi: 10.1111/tid.12064
pubmed: 23465046
Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2008;14:1231–8.
doi: 10.1016/j.bbmt.2008.08.008
Rasheed W, Ghavamzadeh A, Hamladji R, Ben Othman T, Alseraihy A, Abdel-Rahman F, et al. Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey. Hematol Oncol Stem Cell Ther. 2013;6:14–9.
doi: 10.1016/j.hemonc.2013.04.001
pubmed: 23664600
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2016;27:v111–8.
doi: 10.1093/annonc/mdw325
pubmed: 27664247
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–212.
doi: 10.1200/JCO.2015.62.3488
pubmed: 26169616
Gupta AK, Meena JP, Haldar P, Tanwar P, Seth R. Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res. 2021;11:544–63.
pubmed: 34824887
pmcid: 8610798
Lehrnbecher T, Averbuch D, Castagnola E, Cesaro S, Ammann RA, Garcia-Vidal C, et al. 8th European Conference on Infections in Leukaemia. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22:e270–e280.
doi: 10.1016/S1470-2045(20)30725-7
pubmed: 33811814
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N. Engl J Med. 2017;377:2433–44.
doi: 10.1056/NEJMoa1706640
pubmed: 29211658
Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, et al. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524.
doi: 10.3389/fimmu.2020.00524
pubmed: 32296434
pmcid: 7137396
Agreiter I, Kozijn AE, Bakunina K, Averbuch D, Stringer J, Hutt D, et al. Nurses Group and Infectious Diseases Working Party of EBMT. Contribution of nurses to protective environment in haematopoietic cell transplant setting: an international survey by the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2021;56:1433–40.
doi: 10.1038/s41409-020-01194-6